Rosella  Ombrato

Rosella Ombrato

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2020 in Molecules
Verified
Journal Article
Open access
PDF file
RBRosa Buonfiglio
Rosa Buonfiglio
FPFederica Prati
Federica Prati
MBMartina Bischetti
Martina Bischetti
CCClaudia Cavarischia
Claudia Cavarischia
GFGuido Furlotti
Guido Furlotti
RORosella Ombrato
Rosella Ombrato
The interest of research groups and pharmaceutical companies to discover novel GSK-3β inhibitors has increased over the years considering the involvement of this enzyme in many pathophysiological processes and diseases. Along this line, we recently reported on 1H-indazole-3-carboxamide (INDZ) derivatives 1–6, showing good GSK-3β inhibition activity. However, they suffered from generally poor central nervous system (CNS) permeability. Here, we describe the design, synthesis, and in vitro characterization of novel imidazo[1,5-a]pyridine-1-carboxamide (IMID 1) and imidazo[1,5-a]pyridine-3-carboxamide (IMID 2) compounds (7–18) to overcome such liability. In detail, structure-based approaches and fine-tuning of physicochemical properties guided the design of derivatives 7–18 resulting in ameliorated absorption, distribution, metabolism, and excretion (ADME) properties. A crystal structure of 16 in complex with GSK-3β enzyme (PDB entry 6Y9S) confirmed the in silico models. Despite the nanomolar inhibition activity, the new core compounds showed a reduction in potency with respect to INDZ derivatives 1–6. In this context, Molecular Dynamics (MD) and Quantum Mechanics (QM) based approaches along with NMR investigation helped to rationalize the observed structure activity relationship (SAR). With these findings, the key role of the acidic hydrogen of the central core for a tight interaction within the ATP pocket of the enzyme reflecting in good GSK-3β affinity was demonstrated.

24 March 2020 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
FPFederica Prati
Federica Prati
RBRosa Buonfiglio
Rosa Buonfiglio
GFGuido Furlotti
Guido Furlotti
CCClaudia Cavarischia
Claudia Cavarischia
GMGiorgina Mangano
Giorgina Mangano
RORosella Ombrato
Rosella Ombrato

5 July 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GMGabriele Magaro'
Gabriele Magaro'
FPFederica Prati
Federica Prati
BGBarbara Garofalo
Barbara Garofalo
GCGaia Corso
Gaia Corso
GFGuido Furlotti
Guido Furlotti
RORosella Ombrato
Rosella Ombrato

25 June 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
BGBarbara Garofalo
Barbara Garofalo
FPFederica Prati
Federica Prati
RBRosa Buonfiglio
Rosa Buonfiglio
ICIsabella Coletta
Isabella Coletta
NDNoemi D’atanasio
Noemi D’atanasio
RORosella Ombrato
Rosella Ombrato
The major cause of bacterial resistance to β-lactams is the production of hydrolytic β-lactamase enzymes. Nowadays, the combination of β-lactam antibiotics with β-lactamase inhibitors (BLIs) is the main strategy for overcoming such issues. Nevertheless, particularly challenging β-lactamases, such as OXA-48, pose the need for novel and effective treatments. Herein, we describe the screening of a proprietary compound collection against Klebsiella pneumoniae OXA-48, leading to the identification of several chemotypes, like the 4-ideneamino-4H-1,2,4-triazole (SC_2) and pyrazolo[3,4-b]pyridine (SC_7) cores as potential inhibitors. Importantly, the most potent representative of the latter series (ID2, AC50 = 0.99 μM) inhibited OXA-48 via a reversible and competitive mechanism of action, as demonstrated by biochemical and X-ray studies; furthermore, it slightly improved imipenem’s activity in Escherichia coli ATCC BAA-2523 β-lactam resistant strain. Also, ID2 showed good solubility and no sign of toxicity up to the highest tested concentration, resulting in a promising starting point for further optimization programs toward novel and effective non-β-lactam BLIs.

3 March 2022 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
BGBarbara Garofalo
Barbara Garofalo
ABAlexandre M.J.J. Bonvin
Alexandre M.J.J. Bonvin
ABAndrea Bosin
Andrea Bosin
FGFrancesco P. Di Giorgio
Francesco P. Di Giorgio
RORosella Ombrato
Rosella Ombrato
Attilio VargiuAttilio Vargiu
Attilio Vargiu
Voltage-gated potassium channels of the Kv7.x family are involved in a plethora of biological processes across many tissues in animals, and their misfunctioning could lead to several pathologies ranging from diseases caused by neuronal hyperexcitability, such as epilepsy, or traumatic injuries and painful diabetic neuropathy to autoimmune disorders. Among the members of this family, the Kv7.2 channel can form hetero-tetramers together with Kv7.3, forming the so-called M-channels, which are primary regulators of intrinsic electrical properties of neurons and of their responsiveness to synaptic inputs. Here, prompted by the similarity between the M-current and that in Kv7.2 alone, we perform a computational-based characterization of this channel in its different conformational states and in complex with the modulator retigabine. After validation of the structural models of the channel by comparison with experimental data, we investigate the effect of retigabine binding on the two extreme states of Kv7.2 (resting-closed and activated-open). Our results suggest that binding, so far structurally characterized only in the intermediate activated-closed state, is possible also in the other two functional states. Moreover, we show that some effects of this binding, such as increased flexibility of voltage sensing domains and propensity of the pore for open conformations, are virtually independent on the conformational state of the protein. Overall, our results provide new structural and dynamic insights into the functioning and the modulation of Kv7.2 and related channels.